A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until study week 12 in patients with neovascular (wet) age-related macular degeneration

Trial Profile

A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until study week 12 in patients with neovascular (wet) age-related macular degeneration

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2017

At a glance

  • Drugs Ranibizumab (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms TIDE AMD
  • Sponsors Novartis
  • Most Recent Events

    • 24 May 2017 Planned End Date changed from 1 May 2017 to 3 Sep 2017.
    • 24 May 2017 Planned primary completion date changed from 1 May 2017 to 3 Sep 2017.
    • 11 Nov 2016 Planned End Date changed from 1 Sep 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top